Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow. sounds like Boodogs wild speculation might not be that "wild" after all.
He said CE mark early 2017. Trials sometime in 2017. He was very excited about doing a 510k submission in U.S.
Seems to me there is still a long arduous process before this is commercially viable. Probably early 2018 for Europe and 2019 or 2020 for U.S. Really hope they sign a JV or partnership sometime next year. I could be wrong but it doesn't appear that a partnership is imminent. JMO but I am guessing the climb to over a buck is going to be much slower than anticipated by many. The bright side is there appears to be a lot going on behind the scenes and even if it takes a year to crest a dollar that's still an 80% plus gain from where we are at.
False alarm.
On or around December 1, 2016, in accordance with the terms of the Amendment and Supplement, the Issuer issued the ANDA Shares to Holdings without regarding to whether the ANDA Approval had been obtained. Holdings and the Issuer entered into the Amendment and Supplement in order to, among other things, extend the date by which the Issuer is required to register the shares of the Common Stock held by Holdings and waive any rights Holdings may have had with respect to inclusion of shares of the Common Stock held by Holdings in registration statements previously filed by Issuer.
This should be the month when they announce info about next years trials.
Innovus Pharma Launches its Clinically Proven UriVarx™ Product for Bladder Health Through its Beyond Human® Sales and Marketing Platform in the United States
UriVarx™ Sales Expected to Contribute $3 Million in Annual Revenue
Known that it would happen yes. When, no we didn't know. I am not claiming there is a problem just stating that it is probably why the price isn't currently going higher. Everyone I have seen post including myself thought we would be north of a dollar by this time of the year. Once we churn through the additional shares I feel sure we will be albeit maybe not in 2016. Still up almost 200% for me so it is easy to be patient.
The Offering
This prospectus relates to the resale from time to time by the selling securityholders identified in this prospectus of up to 16,531,508 shares of our Common Stock issued or underlying the Series D Warrants issued in the 2015 Private Placement Financing. None of the shares to be registered hereby are being offered for sale by us.
Common Stock outstanding prior to November 25, 2016 137,857,075 (1)
Common Stock offered by the selling securityholders 16,531,508 (2)
Common Stock to be outstanding after the offering 148,763,738 (3)
[color=red][/color]
Almost a 10% increase in outstanding shares. Now at 148 million. Explains why price isn't going up.
It would be nice to have a press release to focus on. Lol
Could be a prelude to fluticare approval.
I agree. Unforturnately the only thing the market cares about with this stock is fluticare
256k on bid WOW
Anybody know if Arch has plans for an annual shareholders meeting?
Dr. Norchi is the one running the show here so Dr. Dhillon's "debatable" record isn't an issue. I haven't seen you assail Dr. Norchi's record.
I am curious. Since you put so much stock in the day financials are reported what is your prediction? Reporting after hours on Thursday effectively makes it a Friday report. What are your revenue predictions and do you think it is a good or bad number?
Any increase in authorized shares creates a greater potential for dilution. If the shares are issued judiciously and for the right reasons it mitigates the downside. Some of the good reasons include issuance to retain or recruit executives, mergers and acquisitions, and as antitakeover measures. there are also a myriad of well known wrong reasons to issue shares. The report states the company has no immediate plans for issuing the afore mentioned increased authorized shares. It comes down to how much you trust the management team. Either way make sure you vote your proxy so there is a quorum.
Hope this helps.
I saw the filing but can't find the updated presentation on their website page. Where is it.
I agree with you. Just assuming the filings are the explanation for the muted share price
One of them added 1.2 million shares to o/s yesterday
See 3 s-3 filings last night
Excellent! Good DD on your part.
Are you sure you didn't mistake that with arch coal?
I don't know if is that or the shelf registration or an unnamed jv but Norchi does not seem at all concerned about the company needing money. Most likely it is a combination of all three. I very impressed so far in his leadership.
I listened to the presentation. One of the exciting new things was Dr. Norchi said the company just received a new patent. In layman's terms it is the ability to add other substances to the AC5. just as people on this board speculated about how great it would be to combine say an antibiotic to AC5, the company has now patented that ability. He also said the final results should be out "immanently". He also said there are a lot of warrants that are now in the money that can be exercised at the owners discretion. My impression is Norchi continues to be extremely pleased and excited about where the company is and is headed. Guessing they will be PR'ing the Patent news very soon.
Thanks for sharing. I personally think the article puts too much emphasis on uplisting. I don't think that is a near term priority for Norchi. He recently stated they are working on more collaborative efforts besides Curam. I think he plans on having the money for the upcoming year without r/s and uplisting to raise money. Eventually nasdaq and possibly an r/s but further down the road and at a significantly higher price point than where we are currently. I think Norchi believes organic up listing is still a ppssibility.
according to IR end of this year.
I don't think Norchi is interested in a buyout anytime soon.
They announced approval of clinical trials last year in December. It has taken almost a year and we still don't have the final results. If they plan on having more trials completed in 2017 then they will have to announce the approval of them pretty soon.
I had the impression that final results and then the peer review were needed before CE mark application would happen. If so then CE mark application probably won't happen until first quarter next year.
I agree but when this finally takes off it will be parabolic
I will be happy if we close above 50 dma
Nothing new. Same things they have been saying since August.
LMAO!
Big bid support today
Just a hunch but I think we see final results this week or next.
Dilution yes but IMO with the right partner and for the right reason is acceptable and good for the long term good of the company.